A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

2003 • 2,642 citations

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 • 2,565 citations

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

1998 • 1,551 citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 • 1,520 citations

p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest

1994 • 1,475 citations

How Proteolysis Drives the Cell Cycle

1996 • 1,277 citations

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 • 771 citations

Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

1998 • 674 citations

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

2002 • 462 citations

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

2002 • 446 citations

The Treatment of Multiple Myeloma

1994 • 409 citations

The role of the ubiquitin-proteasome pathway in apoptosis

1999 • 382 citations

The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression

1995 • 354 citations

Current Therapy for Multiple Myeloma

2002 • 101 citations

Regulation of transcription factors by protein degradation

2000 • 99 citations

Thalidomide treatment in multiple myeloma

2002 • 30 citations